{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T23:16:05Z","timestamp":1774307765793,"version":"3.50.1"},"reference-count":92,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1016\/j.clinthera.2014.10.012","type":"journal-article","created":{"date-parts":[[2014,11,21]],"date-time":"2014-11-21T03:29:24Z","timestamp":1416540564000},"page":"2096-2111","source":"Crossref","is-referenced-by-count":11,"title":["Role of Clinical Pharmacology in the Development of Antiplatelet Drugs"],"prefix":"10.1016","volume":"36","author":[{"given":"Carlo","family":"Patrono","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2014.10.012_bib1","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1136\/bmj.1.5905.436","article-title":"A randomized controlled trial of acetyl salicylic acid in the secondary prevention of mortality from myocardial infarction","volume":"1","author":"Elwood","year":"1974","journal-title":"BMJ"},{"key":"10.1016\/j.clinthera.2014.10.012_bib2","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1056\/NEJM197807132990201","article-title":"A randomized trial of aspirin and sulfinpyrazone in threatened stroke","volume":"299","year":"1978","journal-title":"N Engl J Med"},{"issue":"suppl","key":"10.1016\/j.clinthera.2014.10.012_bib3","doi-asserted-by":"crossref","first-page":"S241","DOI":"10.1038\/sj.bjp.0706401","article-title":"Antiplatelet drugs","volume":"147","author":"Born","year":"2006","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.clinthera.2014.10.012_bib4","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJM198401263100401","article-title":"Effect of dipyridamole and aspirin on late vein-graft patency after coronary bypass operations","volume":"310","author":"Chesebro","year":"1984","journal-title":"N Engl J Med"},{"issue":"suppl","key":"10.1016\/j.clinthera.2014.10.012_bib5","doi-asserted-by":"crossref","first-page":"234S","DOI":"10.1378\/chest.126.3_suppl.234S","article-title":"Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy","volume":"126","author":"Patrono","year":"2004","journal-title":"Chest"},{"key":"10.1016\/j.clinthera.2014.10.012_bib6","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1056\/NEJM199501263320408","article-title":"Drugs and surgery in the prevention of ischemic stroke","volume":"332","author":"Barnett","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2014.10.012_bib7","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1056\/NEJM199405053301808","article-title":"Aspirin as an antiplatelet drug","volume":"330","author":"Patrono","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2014.10.012_bib8","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","article-title":"Antithrombotic Trialists\u02bc Collaboration, Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients","volume":"324","year":"2002","journal-title":"BMJ"},{"key":"10.1016\/j.clinthera.2014.10.012_bib9","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(09)60503-1","article-title":"Antithrombotic Trialists\u02bc Collaboration, Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials","volume":"373","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2014.10.012_bib10","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.1093\/eurheartj\/ehr373","article-title":"Antiplatelet agents for the treatment and prevention of atherothrombosis","volume":"32","author":"Patrono","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.clinthera.2014.10.012_bib11","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1093\/eurheartj\/eht058","article-title":"Low-dose aspirin in primary prevention: cardioprotection, chemoprevention, both, or neither?","volume":"34","author":"Patrono","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.clinthera.2014.10.012_bib12","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1056\/NEJMra052717","article-title":"Low-dose aspirin for the prevention of atherothrombosis","volume":"353","author":"Patrono","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2014.10.012_bib13","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.jacc.2008.10.047","article-title":"Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: implications for aspirin \u201cresistance\u201d","volume":"53","author":"Santilli","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.clinthera.2014.10.012_bib14","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1172\/JCI108941","article-title":"Inhibition of platelet prostaglandin synthetase by oral aspirin","volume":"612","author":"Burch","year":"1978","journal-title":"J Clin Invest"},{"key":"10.1016\/j.clinthera.2014.10.012_bib15","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1172\/JCI110576","article-title":"Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects","volume":"69","author":"Patrignani","year":"1982","journal-title":"J Clin Invest"},{"key":"10.1016\/j.clinthera.2014.10.012_bib16","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1172\/JCI110814","article-title":"Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man","volume":"71","author":"FitzGerald","year":"1983","journal-title":"J Clin Invest"},{"key":"10.1016\/j.clinthera.2014.10.012_bib17","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/0049-3848(80)90066-3","article-title":"Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects","volume":"17","author":"Patrono","year":"1980","journal-title":"Thromb Res"},{"key":"10.1016\/j.clinthera.2014.10.012_bib18","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1161\/01.CIR.72.6.1177","article-title":"Clinical pharmacology of platelet cyclooxygenase inhibition","volume":"72","author":"Patrono","year":"1985","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2014.10.012_bib19","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1056\/NEJM198411083111902","article-title":"Dose-related kinetics of aspirin. Presystemic acetylation of platelet cyclooxygenase","volume":"311","author":"Pedersen","year":"1984","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2014.10.012_bib20","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1056\/NEJM199110173251605","article-title":"Suppression of thromboxane A2 but not of systemic prostacyclin by controlled-release aspirin","volume":"325","author":"Clarke","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2014.10.012_bib21","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1073\/pnas.96.1.272","article-title":"Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2","volume":"96","author":"McAdam","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.clinthera.2014.10.012_bib22","first-page":"349","article-title":"ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2","volume":"2","year":"1988","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2014.10.012_bib23","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1172\/JCI112341","article-title":"Estimated rate of thromboxane secretion into the circulation of normal humans","volume":"77","author":"Patrono","year":"1986","journal-title":"J Clin Invest"},{"key":"10.1016\/j.clinthera.2014.10.012_bib24","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1056\/NEJM198610163151602","article-title":"Platelet activation in unstable coronary disease","volume":"315","author":"Fitzgerald","year":"1986","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2014.10.012_bib25","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1055\/s-0038-1645038","article-title":"Dissociation of platelet activation and spontaneous myocardial ischemia in unstable angina","volume":"63","author":"Vejar","year":"1990","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.clinthera.2014.10.012_bib26","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1161\/01.STR.24.2.219","article-title":"Increased thromboxane biosynthesis in patients with acute cerebral ischemia","volume":"24","author":"Koudstaal","year":"1993","journal-title":"Stroke"},{"key":"10.1016\/j.clinthera.2014.10.012_bib27","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1161\/01.STR.25.2.278","article-title":"Evidence for episodic platelet activation in acute ischemic stroke","volume":"25","author":"van Kooten","year":"1994","journal-title":"Stroke"},{"key":"10.1016\/j.clinthera.2014.10.012_bib28","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1056\/NEJM199006213222503","article-title":"Thromboxane biosynthesis and platelet function in type II diabetes mellitus","volume":"322","author":"Dav\u00ec","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2014.10.012_bib29","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1161\/01.CIR.85.5.1792","article-title":"Increased thromboxane biosynthesis in type IIa hypercholesterolemia","volume":"85","author":"Dav\u00ec","year":"1992","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2014.10.012_bib30","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1172\/JCI116715","article-title":"Abnormally high thromboxane biosynthesis in homozygous homocystinuria. Evidence for platelet involvement and probucol-sensitive mechanism","volume":"92","author":"Di Minno","year":"1993","journal-title":"J Clin Invest"},{"key":"10.1016\/j.clinthera.2014.10.012_bib31","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1161\/01.CIR.96.1.69","article-title":"Diabetes mellitus, hypercholesterolemia, and hypertension but not vascular disease per se are associated with persistent platelet activation in vivo. Evidence derived from the study of peripheral arterial disease","volume":"96","author":"Dav\u00ec","year":"1997","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2014.10.012_bib32","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1001\/jama.288.16.2008","article-title":"Platelet activation in obese women: role of inflammation and oxidant stress","volume":"288","author":"Dav\u00ec","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2014.10.012_bib33","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.1161\/01.CIR.0000039528.49161.E9","article-title":"Increased oxidative stress and platelet activation in patients with hypertension and renovascular disease","volume":"106","author":"Minuz","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2014.10.012_bib34","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1182\/blood-2012-10-429134","article-title":"Platelet activation and inhibition in polycythemia vera and essential thrombocythemia","volume":"121","author":"Patrono","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2014.10.012_bib35","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1056\/NEJM197905173002006","article-title":"Arachidonic acid metabolites and the interactions between platelets and blood-vessel walls","volume":"300","author":"Moncada","year":"1979","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2014.10.012_bib36","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1172\/JCI110373","article-title":"Estimated rate of prostacyclin secretion into the circulation of normal man","volume":"68","author":"FitzGerald","year":"1981","journal-title":"J Clin Invest"},{"key":"10.1016\/j.clinthera.2014.10.012_bib37","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1056\/NEJM198404263101701","article-title":"Increased prostacyclin biosynthesis in patients with severe atherosclerosis and platelet activation","volume":"310","author":"FitzGerald","year":"1984","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2014.10.012_bib38","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1056\/NEJM200108093450607","article-title":"The coxibs, selective inhibitors of cyclooxygenase-2","volume":"345","author":"FitzGerald","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2014.10.012_bib39","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/41780","article-title":"Altered pain perception and inflammatory response in mice lacking prostacyclin receptor","volume":"388","author":"Murata","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.clinthera.2014.10.012_bib40","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1126\/science.1068711","article-title":"Role of prostacyclin in the cardiovascular response to thromboxane A2","volume":"296","author":"Cheng","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.clinthera.2014.10.012_bib41","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1136\/bmj.332.7553.1302","article-title":"Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials","volume":"332","author":"Kearney","year":"2006","journal-title":"BMJ"},{"key":"10.1016\/j.clinthera.2014.10.012_bib42","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/S0140-6736(13)60900-9","article-title":"Coxib and traditional NSAID Trialists\u02bc (CNT) Collaboration, Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials","volume":"382","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2014.10.012_bib43","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/ncpcardio0728","article-title":"Drug insight: aspirin resistance\u2014fact or fashion?","volume":"4","author":"Patrono","year":"2007","journal-title":"Nat Clin Pract Cardiovasc Med"},{"key":"10.1016\/j.clinthera.2014.10.012_bib44","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1161\/01.STR.25.12.2331","article-title":"Development of aspirin resistance in persons with previous ischemic stroke","volume":"25","author":"Helgason","year":"1994","journal-title":"Stroke"},{"key":"10.1016\/j.clinthera.2014.10.012_bib45","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/S0735-1097(02)03014-0","article-title":"A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease","volume":"41","author":"Gum","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.clinthera.2014.10.012_bib46","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1111\/j.1538-7836.2012.04723.x","article-title":"The recovery of platelet cyclooxygenase activity explains interindividual variability in responsiveness to low-dose aspirin in patients with and without diabetes","volume":"10","author":"Rocca","year":"2012","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.clinthera.2014.10.012_bib47","doi-asserted-by":"crossref","first-page":"3595","DOI":"10.1182\/blood-2011-06-359224","article-title":"Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target","volume":"119","author":"Pascale","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2014.10.012_bib48","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1160\/TH05-10-0653","article-title":"Dose- and time-dependent antiplatelet effects of aspirin","volume":"95","author":"Perneby","year":"2006","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.clinthera.2014.10.012_bib49","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1160\/TH10-02-0082","article-title":"24-hour time-dependent aspirin efficacy in patients with stable coronary artery disease","volume":"105","author":"Henry","year":"2011","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.clinthera.2014.10.012_bib50","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/j.jacc.2005.06.058","article-title":"Platelet response to low-dose enteric-coated aspirin in patients with stable cardiovascular disease","volume":"47","author":"Maree","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.clinthera.2014.10.012_bib51","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1161\/CIRCULATIONAHA.112.117283","article-title":"Drug resistance and pseudoresistance. An unintended consequence of enteric coating aspirin","volume":"127","author":"Grosser","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2014.10.012_bib52","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1161\/HYPERTENSIONAHA.111.181404","article-title":"Suboptimal inhibition of platelet cyclooxygenase-1 by aspirin in metabolic syndrome","volume":"59","author":"Smith","year":"2012","journal-title":"Hypertension"},{"key":"10.1016\/j.clinthera.2014.10.012_bib53","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1160\/TH11-04-0216","article-title":"Twice daily dosing of aspirin improves platelet inhibition in whole blood in patients with type 2 diabetes mellitus and micro- or macrovascular complications","volume":"106","author":"Spectre","year":"2011","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.clinthera.2014.10.012_bib54","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.ahj.2012.06.008","article-title":"Biological efficacy of twice daily aspirin in type 2 diabetic patients with coronary artery disease","volume":"164","author":"Dillinger","year":"2012","journal-title":"Am Heart J"},{"key":"10.1016\/j.clinthera.2014.10.012_bib55","doi-asserted-by":"crossref","unstructured":"Authors\/Task Force Members, Ryd\u00e9n L, Grant PJ, et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on Diabetes, Pre-Diabetes, and Cardiovascular Diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD) [erratum in: Eur Heart J 2014 ;35:1824]. Eur Heart J 2013;34:3035-3087.","DOI":"10.1093\/eurheartj\/eht108"},{"key":"10.1016\/j.clinthera.2014.10.012_bib56","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1093\/jnci\/94.4.252","article-title":"Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues","volume":"94","author":"Thun","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.clinthera.2014.10.012_bib57","article-title":"Cyclooxygenase inhibitors: from pharmacology to clinical read-outs","author":"Patrignani","year":"2014","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.clinthera.2014.10.012_bib58","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/S1470-2045(12)70112-2","article-title":"Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials","volume":"13","author":"Algra","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clinthera.2014.10.012_bib59","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/nrclinonc.2011.199","article-title":"The role of aspirin in cancer prevention","volume":"9","author":"Thun","year":"2012","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.clinthera.2014.10.012_bib60","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1161\/CIRCULATIONAHA.113.004480","article-title":"Nonsteroidal anti-inflammatory drugs and the heart","volume":"129","author":"Patrono","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2014.10.012_bib61","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1016\/S0140-6736(10)61543-7","article-title":"Long-term effect of aspirin on colorectal cancer incidence and mortality: 20 year follow-up of five randomised trials","volume":"376","author":"Rothwell","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2014.10.012_bib62","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(10)62110-1","article-title":"Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials","volume":"377","author":"Rothwell","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2014.10.012_bib63","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1016\/S0140-6736(11)61720-0","article-title":"Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials","volume":"379","author":"Rothwell","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2014.10.012_bib64","doi-asserted-by":"crossref","first-page":"77","DOI":"10.7326\/0003-4819-159-2-201307160-00002","article-title":"Alternate-day, low-dose aspirin and cancer risk: long-term observational follow-up of a randomized trial","volume":"159","author":"Cook","year":"2013","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clinthera.2014.10.012_bib65","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1172\/JCI200113418","article-title":"Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs","volume":"108","author":"Patrono","year":"2001","journal-title":"J Clin Invest"},{"key":"10.1016\/j.clinthera.2014.10.012_bib66","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1124\/mol.113.084988","article-title":"Pharmacological inhibition of platelet-tumor cell cross-talk prevents platelet-induced overexpression of cyclooxygenase-2 in HT29 human colon carcinoma cells","volume":"84","author":"Dovizio","year":"2013","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.clinthera.2014.10.012_bib67","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1111\/jth.12637","article-title":"Reappraisal of the clinical pharmacology of low-dose aspirin by comparing novel direct and traditional indirect biomarkers of drug action","volume":"12","author":"Patrignani","year":"2014","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.clinthera.2014.10.012_bib68","unstructured":"University College London, Medical Research Council, Clinical Trials Unit. Welcome to the Add-Aspirin website. www.addaspirintrial.org. Accessed 30 July, 2014."},{"key":"10.1016\/j.clinthera.2014.10.012_bib69","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1146\/annurev-med-020209-171035","article-title":"The future of antiplatelet therapy in cardiovascular disease","volume":"61","author":"Patrono","year":"2010","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.clinthera.2014.10.012_bib70","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1056\/NEJMoa0808227","article-title":"French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) Investigators. Genetic determinants of response to clopidogrel and cardiovascular events","volume":"360","author":"Simon","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2014.10.012_bib71","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.1161\/CIRCULATIONAHA.107.740324","volume":"116","author":"Wiviott","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2014.10.012_bib72","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1093\/eurheartj\/ehm545","article-title":"Prasugrel achieves greater and faster P2Y12 receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease","volume":"29","author":"Wallentin","year":"2008","journal-title":"Eur Heart J"},{"key":"10.1016\/j.clinthera.2014.10.012_bib73","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1093\/eurheartj\/ehi754","article-title":"Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin","volume":"27","author":"Husted","year":"2006","journal-title":"Eur Heart J"},{"key":"10.1016\/j.clinthera.2014.10.012_bib74","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1161\/CIRCULATIONAHA.109.912550","article-title":"Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET\/OFFSET study","volume":"120","author":"Gurbel","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2014.10.012_bib75","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2014.10.012_bib76","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2014.10.012_bib77","unstructured":"Comparative Effectiveness of 1 Month of Ticagrelor Plus Aspirin Followed by Ticagrelor Monotherapy Versus a Current-day Intensive Dual Antiplatelet Therapy in All-comers Patients Undergoing Percutaneous Coronary Intervention With Bivalirudin and BioMatrix Family Drug-eluting Stent Use ClinicalTrials.gov. Identifier:NCT01813435. Accessed July 30, 2014."},{"key":"10.1016\/j.clinthera.2014.10.012_bib78","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1172\/JCI110973","article-title":"A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombasthenic-like state in normal platelets and binds to glycoproteins IIb and\/or IIIa","volume":"72","author":"Coller","year":"1983","journal-title":"J Clin Invest"},{"key":"10.1016\/j.clinthera.2014.10.012_bib79","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1161\/01.CIR.92.9.2373","article-title":"Blockade of platelet GPIIb\/IIIa receptors as an antithrombotic strategy","volume":"92","author":"Coller","year":"1995","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2014.10.012_bib80","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1161\/01.CIR.103.2.201","article-title":"Increased mortality with oral platelet glycoprotein IIb\/IIIa antagonists: a meta-analysis of phase III multicenter randomized trials","volume":"103","author":"Chew","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2014.10.012_bib81","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1056\/NEJMra071014","article-title":"Platelet activation and atherothrombosis","volume":"357","author":"Dav\u00ec","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2014.10.012_bib82","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1111\/j.1538-7836.2010.04020.x","article-title":"TAIPAD investigators. Thromboxane Antagonism with terutroban in Peripheral Arterial Disease: the TAIPAD study","volume":"8","author":"Fiessinger","year":"2010","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.clinthera.2014.10.012_bib83","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1016\/S0140-6736(11)60600-4","article-title":"PERFORM Study Investigators. Terutroban versus aspirin in patients with cerebral ischaemic events (PERFORM): a randomised, double-blind, parallel-group trial","volume":"377","author":"Bousser","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2014.10.012_bib84","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1111\/j.1538-7836.2005.01377.x","article-title":"Protease-activated receptors in hemostasis, thrombosis and vascular biology","volume":"3","author":"Coughlin","year":"2005","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.clinthera.2014.10.012_bib85","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S0140-6736(09)60230-0","article-title":"TRA-PCI Investigators. Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study","volume":"373","author":"Becker","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2014.10.012_bib86","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa1109719","article-title":"TRACER Investigators. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes","volume":"366","author":"Tricoci","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2014.10.012_bib87","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1056\/NEJMoa1200933","article-title":"TRA 2P\u2013TIMI 50 Steering Committee and Investigators. Vorapaxar in the secondary prevention of atherothrombotic events","volume":"366","author":"Morrow","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2014.10.012_bib88","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/S0140-6736(12)61269-0","article-title":"TRA 2\u00b0P-TIMI 50 Steering Committee and Investigators. Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2\u00b0P-TIMI 50 trial","volume":"380","author":"Scirica","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2014.10.012_bib89","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1161\/CIRCULATIONAHA.112.000679","article-title":"Vorapaxar in patients with peripheral artery disease: results from TRA 2P-TIMI 50","volume":"127","author":"Bonaca","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2014.10.012_bib90","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1161\/STROKEAHA.111.000433","article-title":"Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events\u2013TIMI 50 Steering Committee and Investigators. Efficacy and safety of vorapaxar in patients with prior ischemic stroke","volume":"44","author":"Morrow","year":"2013","journal-title":"Stroke"},{"key":"10.1016\/j.clinthera.2014.10.012_bib91","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(96)09457-3","article-title":"A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events","volume":"348","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2014.10.012_bib92","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1056\/NEJMoa060989","article-title":"CHARISMA Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events","volume":"354","author":"Bhatt","year":"2006","journal-title":"N Engl J Med"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291814006857?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291814006857?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,4,23]],"date-time":"2022-04-23T00:40:39Z","timestamp":1650674439000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291814006857"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12]]},"references-count":92,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["S0149291814006857"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2014.10.012","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2014,12]]}}}